-
Je něco špatně v tomto záznamu ?
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis
GR. Burmester, IB. McInnes, JM. Kremer, P. Miranda, J. Vencovský, A. Godwood, M. Albulescu, MA. Michaels, X. Guo, D. Close, M. Weinblatt,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, fáze II, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
29361199
DOI
10.1002/art.40420
Knihovny.cz E-zdroje
- MeSH
- antirevmatika terapeutické užití MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- monoklonální protilátky terapeutické užití MeSH
- následné studie MeSH
- receptory faktoru stimulujícího granulocyto-makrofágové kolonie terapeutické užití MeSH
- revmatoidní artritida farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor α. We undertook to determine the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open-label extension study (ClinicalTrials.gov identifier: NCT01712399). METHODS: In study 1071, patients with an inadequate response to disease-modifying antirheumatic drugs (DMARDs) received mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate. In study 1107, patients with an inadequate response to anti-tumor necrosis factor agents and/or DMARDs received 100 mg mavrilimumab every other week or 50 mg golimumab every 4 weeks plus methotrexate. Patients entering the open-label extension study received 100 mg mavrilimumab every other week plus methotrexate. Long-term safety and efficacy of mavrilimumab were assessed. RESULTS: A total of 442 patients received mavrilimumab (14 of 245 patients from study 1071, 9 of 70 patients from study 1107, and 52 of 397 patients from the open-label extension study discontinued mavrilimumab treatment throughout the studies). The cumulative safety exposure was 899 patient-years; the median duration of mavrilimumab treatment was 2.5 years (range 0.1-3.3 years). The most common treatment-emergent adverse events (AEs) were nasopharyngitis (n = 69; 7.68 per 100 patient-years) and bronchitis (n = 51; 5.68 per 100 patient-years). At weeks 74 and 104, 3.5% and 6.2% of patients, respectively, demonstrated reduction in forced expiratory volume in 1 second, while 2.9% and 3.4% of patients, respectively, demonstrated reduction in forced vital capacity (>20% reduction from baseline to <80% predicted). Most pulmonary changes were transient and only infrequently associated with AEs. Mavrilimumab at 100 mg every other week demonstrated sustained efficacy; at week 122, 65.0% of patients achieved a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <3.2, and 40.6% of patients achieved a DAS28-CRP of <2.6. CONCLUSION: Long-term treatment with mavrilimumab maintained response and was well-tolerated with no increased incidence of treatment-emergent AEs. Safety data were comparable with those from both phase IIb qualifying studies.
Brigham and Women's Hospital Boston Massachusetts
Centro de Estudios Reumatológicos Santiago Chile
Charité University Medicine Berlin Berlin Germany
Institute of Rheumatology Prague Czech Republic
MedImmune Gaithersburg Maryland
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028605
- 003
- CZ-PrNML
- 005
- 20190816104703.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/art.40420 $2 doi
- 035 __
- $a (PubMed)29361199
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Burmester, Gerd R $u Charité - University Medicine Berlin, Berlin, Germany.
- 245 10
- $a Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis / $c GR. Burmester, IB. McInnes, JM. Kremer, P. Miranda, J. Vencovský, A. Godwood, M. Albulescu, MA. Michaels, X. Guo, D. Close, M. Weinblatt,
- 520 9_
- $a OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor α. We undertook to determine the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open-label extension study (ClinicalTrials.gov identifier: NCT01712399). METHODS: In study 1071, patients with an inadequate response to disease-modifying antirheumatic drugs (DMARDs) received mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate. In study 1107, patients with an inadequate response to anti-tumor necrosis factor agents and/or DMARDs received 100 mg mavrilimumab every other week or 50 mg golimumab every 4 weeks plus methotrexate. Patients entering the open-label extension study received 100 mg mavrilimumab every other week plus methotrexate. Long-term safety and efficacy of mavrilimumab were assessed. RESULTS: A total of 442 patients received mavrilimumab (14 of 245 patients from study 1071, 9 of 70 patients from study 1107, and 52 of 397 patients from the open-label extension study discontinued mavrilimumab treatment throughout the studies). The cumulative safety exposure was 899 patient-years; the median duration of mavrilimumab treatment was 2.5 years (range 0.1-3.3 years). The most common treatment-emergent adverse events (AEs) were nasopharyngitis (n = 69; 7.68 per 100 patient-years) and bronchitis (n = 51; 5.68 per 100 patient-years). At weeks 74 and 104, 3.5% and 6.2% of patients, respectively, demonstrated reduction in forced expiratory volume in 1 second, while 2.9% and 3.4% of patients, respectively, demonstrated reduction in forced vital capacity (>20% reduction from baseline to <80% predicted). Most pulmonary changes were transient and only infrequently associated with AEs. Mavrilimumab at 100 mg every other week demonstrated sustained efficacy; at week 122, 65.0% of patients achieved a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <3.2, and 40.6% of patients achieved a DAS28-CRP of <2.6. CONCLUSION: Long-term treatment with mavrilimumab maintained response and was well-tolerated with no increased incidence of treatment-emergent AEs. Safety data were comparable with those from both phase IIb qualifying studies.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a revmatoidní artritida $x farmakoterapie $7 D001172
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a receptory faktoru stimulujícího granulocyto-makrofágové kolonie $x terapeutické užití $7 D016187
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a McInnes, Iain B $u University of Glasgow, Glasgow, UK.
- 700 1_
- $a Kremer, Joel M $u The Albany Medical College, Albany, New York.
- 700 1_
- $a Miranda, Pedro $u Centro de Estudios Reumatológicos, Santiago, Chile.
- 700 1_
- $a Vencovský, Jiří $u Institute of Rheumatology, Prague, Czech Republic.
- 700 1_
- $a Godwood, Alex $u MedImmune, Cambridge, UK.
- 700 1_
- $a Albulescu, Marius $u MedImmune, Cambridge, UK.
- 700 1_
- $a Michaels, M Alex $u MedImmune, Gaithersburg, Maryland.
- 700 1_
- $a Guo, Xiang $u MedImmune, Gaithersburg, Maryland.
- 700 1_
- $a Close, David $u MedImmune, Cambridge, UK.
- 700 1_
- $a Weinblatt, Michael $u Brigham and Women's Hospital, Boston, Massachusetts.
- 773 0_
- $w MED00188151 $t Arthritis & rheumatology (Hoboken, N.J.) $x 2326-5205 $g Roč. 70, č. 5 (2018), s. 679-689
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29361199 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190816104932 $b ABA008
- 999 __
- $a ok $b bmc $g 1433754 $s 1067065
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 70 $c 5 $d 679-689 $e 20180331 $i 2326-5205 $m Arthritis & rheumatology $n Arthritis Rheumatol $x MED00188151
- LZP __
- $a Pubmed-20190813